PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2020.7812021361157-170Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse ModelJin Hee Kim, Gha Young Lee, Hyo Jin Maeng, Hoyoun Kim, Jae Hyun Bae, Kyoung Min Kim, Soo Limhttp://e-enm.org/upload/pdf/enm-2020-781.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2020.781, http://e-enm.org/upload/pdf/enm-2020-781.pdf
Endocrinology and Metabolism10.3803/enm.2021.109202136157-59Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 DiabetesJang Won Sonhttp://e-enm.org/upload/pdf/enm-2021-109.pdf, http://e-enm.org/journal/view.php?doi=10.3803/EnM.2021.109, http://e-enm.org/upload/pdf/enm-2021-109.pdf
Diabetes10.2337/db13-07102013631101-110Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor–Deficient MiceBilal A. Omar, Birgitte Andersen, Jacob Hald, Kirsten Raun, Erica Nishimura, Bo Ahrénhttps://journals.org/diabetes/diabetes/article-pdf/63/1/101/572758/101.pdf, https://journals.org/diabetes/diabetes/article-pdf/63/1/101/572758/101.pdf
Diabetes, Obesity and Metabolism10.1111/dom.146402022245788-805Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetesChristophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaalhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14640, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dom.14640, https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14640
Atherosclerosis10.1016/j.atherosclerosis.2015.04.89820152411e178-e179Effects of body weight reduction on plasma fibroblast growth factor 21 in obese patients with type 1 diabetes mellitusF. Musil, V. Blaha, A. Ticha, R. Hyspler, M. Haluzik, J. Lesna, A. Smahelova, L. Sobotkahttps://api.elsevier.com/content/article/PII:S0021915015011193?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915015011193?httpAccept=text/plain
Diabetes10.2337/db18-2231-pub201867Supplement_1Combination of Premixed Insulin with Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) for Uncontrolled Type 2 Diabetes Mellitus (T2DM) PatientsSASAN FAZELI, NICOLE EHRHARDThttps://diabetesjournals.org/diabetes/article/67/Supplement_1/2231-PUB/55704/Combination-of-Premixed-Insulin-with-Glucagon-Like, https://diabetesjournals.org/diabetes/article/67/Supplement_1/2231-PUB/55704/Combination-of-Premixed-Insulin-with-Glucagon-Like
Diabetic Medicine10.1111/j.1466-5468.2004.1180h.x200421s118-20Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of Type 2 diabetesJ. Rachmanhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1466-5468.2004.1180h.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1466-5468.2004.1180h.x/fullpdf
Atherosclerosis10.1016/j.atherosclerosis.2018.06.4492018275e151Fibroblast growth factor 21 serum concentrations in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (DM2).M. Walus-miarka, B. Idzior-Walus, M. Kapusta, A. Trojak, P. Miarka, M.T. Maleckihttps://api.elsevier.com/content/article/PII:S0021915018307615?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915018307615?httpAccept=text/plain
Diabetes10.2337/db18-166-or201867Supplement_1Serum Fibroblast Growth Factor-21 Is Related to Atherosclerosis Independent of Nonalcoholic Fatty Liver Disease and Predicts Incident Atherosclerotic Cardiovascular DiseasesLIANG WU, LINGLING QIAN, HUATING LI, WEIPING JIAhttps://diabetesjournals.org/diabetes/article/67/Supplement_1/166-OR/54304/Serum-Fibroblast-Growth-Factor-21-Is-Related-to, https://diabetesjournals.org/diabetes/article/67/Supplement_1/166-OR/54304/Serum-Fibroblast-Growth-Factor-21-Is-Related-to
Diabetes mellitus10.14341/dm96232018214293-300Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetesNina A. Petunina, Milena Е. Telnovahttps://dia-endojournals.ru/dia/article/viewFile/9623/7382, https://dia-endojournals.ru/dia/article/viewFile/9623/7382